Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $48.52M
• Dividend Yield: N/A
• Average Volume (3M): 62.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 475.53%
• EPS Growth: 89.94%
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 3.50
• Shares Outstanding: 6,795,628
• 10 Day Avg. Volume: 95,087
• 30 Day Avg. Volume: 62,232
• PEG Ratio: -0.07
• Price to Book (P/B): -1.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.61
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 0.14
• Enterprise Value/Gross Profit: 0.86
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: $10.00
• Price Target Upside: 40.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $7.00 ▼( -1.96% Downside)

The overall score reflects significant financial challenges, with high liabilities and ongoing cash burn despite revenue growth. Positive technical indicators and corporate events provide some optimism, but valuation concerns and restructuring efforts create uncertainty. The FDA lifting the hold on a key program is a positive regulatory development, but financial stability remains a major concern.

Positive Factors

FDA Approval Process

Atara is laser focused on resubmitting BLA for Ebvallo approval in US.

Partnership and Collaboration

Atara has completed the transfer of all EBVALLO manufacturing to Pierre Fabre, and is solely focusing on BLA resubmission, with additional milestone payments on FDA approval.

Negative Factors

Financial Constraints

Atara announced a reduction in its workforce that will impact approximately 50% of its current employees.

Regulatory Challenges

Tab-cel BLA for treatment of EBV+ PTLD gets FDA rejection.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Atara Biotherapeutics primarily makes money through the development and commercialization of its biopharmaceutical products. The company generates revenue through strategic collaborations and licensing agreements with other pharmaceutical companies and research institutions. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Atara's revenue model is heavily reliant on the successful clinical development, regulatory approval, and commercialization of its drug candidates. Additionally, Atara invests in research and development to expand its pipeline and seek new therapeutic applications for its technologies.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics shows strong revenue growth but remains unprofitable with significant financial risks due to high liabilities and negative cash flow. The negative equity and ongoing cash burn are major concerns, overshadowing the revenue increase.

Income Statement

Atara Biotherapeutics has shown significant revenue growth in 2024, with a notable increase from $8.57 million in 2023 to $128.94 million. However, the company remains unprofitable, with a negative net profit margin and EBIT margin. The gross profit margin improved substantially but is still overshadowed by the consistent net losses over the years.

Balance Sheet

The company exhibits a very high level of liabilities compared to its equity, resulting in a negative stockholders' equity position. This is a significant concern indicating financial instability. The debt-to-equity ratio cannot be computed due to negative equity, highlighting leverage issues. The equity ratio is also negative, underscoring high financial risk.

Cash Flow

Cash flows remain a challenge for Atara Biotherapeutics, with negative operating and free cash flows indicating ongoing cash burn. However, there is a slight improvement in operating cash flow compared to previous years. The free cash flow to net income ratio remains negative, reflecting insufficient cash generation relative to the net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
101.58M	128.94M	8.57M	63.57M	20.34M	0.00
	Gross Profit
62.12M	107.93M	-313.00K	49.01M	8.96M	-9.87M
	EBIT
-13.39M	-83.44M	-276.01M	-280.51M	-340.46M	-309.05M
	EBITDA
-7.76M	-75.75M	-266.00M	-213.72M	-331.12M	-296.74M
	Net Income Common Stockholders
-15.64M	-85.40M	-276.13M	-2.28B	-3.40B	-3.07B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
51.87M	42.50M	51.73M	242.82M	371.07M	500.66M
	Total Assets
165.50M	109.10M	165.50M	376.42M	468.13M	588.12M
	Total Debt
57.87M	43.83M	57.87M	71.70M	25.52M	13.04M
	Net Debt
31.89M	18.80M	32.03M	-21.24M	-80.57M	-187.36M
	Total Liabilities
264.74M	206.38M	264.74M	249.78M	188.51M	125.78M
	Stockholders Equity
-99.23M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow		Free Cash Flow
-67.36M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
	Operating Cash Flow
-67.24M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
	Investing Cash Flow
11.11M	8.62M	123.87M	202.96M	22.26M	-120.73M
	Financing Cash Flow
34.89M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.14
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 7.14 is below the 20-day moving average (MA) of 7.21, above the 50-day MA of 6.72, and below the 200-day MA of 8.75, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.93 is Neutral, neither overbought nor oversold. The STOCH value of 40.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
ATRA	51 Neutral	$48.52M	―	1063.61%	―	475.53%	89.94%
NRXP	45 Neutral	$45.30M	―	108.28%	―	―	41.01%
LTRN	45 Neutral	$35.48M	―	-75.66%	―	―	-31.16%
XFOR	44 Neutral	$17.95M	1.38	121.75%	―	―	―
HOWL	40 Underperform	$51.60M	―	-82.81%	―	-92.95%	-50.02%
KPTI	38 Underperform	$39.66M	―	41.08%	―	1.19%	61.65%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Announces $16M Stock Offering

On May 14, 2024, Atara Biotherapeutics entered into an underwriting agreement with TD Securities (USA) LLC for an underwritten registered direct offering of its common stock and pre-funded warrants, expected to generate approximately $16 million in gross proceeds. The company plans to use the net proceeds to support its biologics license application for tab-cel and for general corporate purposes, with the offering set to close on May 16, 2025.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Appoints New Board Members Amid Restructuring

On May 14, 2025, Atara Biotherapeutics announced the appointment of James Huang and Nachi Subramanian to its Board of Directors following a direct offering of shares and warrants to institutional investors, expected to close on May 16, 2025. The company aims to extend its cash runway through the first quarter of 2026 with the $16 million proceeds, supporting its ongoing activities for potential BLA approval. Atara has transferred manufacturing responsibilities to Pierre Fabre Laboratories, significantly reducing operating expenses, and has paused its CAR T programs while undergoing organizational restructuring, including a 30% workforce reduction.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Announces Major Workforce Reduction

On May 12, 2025, Atara Biotherapeutics, Inc. announced a significant workforce reduction, affecting approximately 30% of its employees, with the aim of retaining around 23 essential staff members to focus on strategic priorities. The company anticipates completing this reduction by August 2025, incurring approximately $1.4 million in severance and related benefits, primarily as one-time cash charges, with further details to be disclosed in their upcoming quarterly report.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

FDA Lifts Hold on Atara’s EBVALLO Program

On May 5, 2025, Atara Biotherapeutics announced that the FDA lifted the clinical hold on its EBVALLO™ (tabelecleucel) program, initially placed in January 2025 due to GMP compliance issues at a third-party manufacturing facility. This decision allows Atara to resume its Phase 3 ALLELE clinical study and a Phase 2 label-expansion study for patients with EBV-associated post-transplant lymphoproliferative disease. Additionally, the FDA granted a Type A meeting to discuss the path forward for resubmitting the Biologics License Application (BLA) for EBVALLO™. Atara has temporarily paused its strategic option evaluation pending clarity on the BLA resubmission timeline.

Atara Biotherapeutics Announces CFO Departure and New Appointment

On March 31, 2025, Atara Biotherapeutics announced the departure of Eric Hyllengren, its Chief Financial Officer and Chief Operating Officer, effective March 31, 2025. Hyllengren will receive severance benefits and his 2024 annual cash bonus, and he will provide consulting services to the company until July 31, 2025. Concurrently, Yanina Grant-Huerta was appointed as the Chief Accounting Officer and principal accounting officer. Grant-Huerta, who has been with the company since 2020, previously served as Vice President of Financial Planning and Analysis.